AJPB
Issue:
May/June 2014
Volume:
6
Number:
3
Drug Trends
Paige Berger
As we shift the healthcare paradigm, new ways to lower costs and improve adherence are worth another look.
From the Editor
Jan E. Berger, MD, MJā€”Editor-in-Chief
There are 10 steps that need to be taken to help payers more adequately address the problem of inappropriate prescribing of pain medications.
Original Research
Jan Berger, MD, MJ; Louis L. Brunetti, MD; Robert DaSilva, RPh; Shareh O. Ghani, MD; Kevin Hirsch, MD; Mumtaz Ibrahim, MD; Michael Kobernick, MD, MS, FAAEM, FAAFP; Robin J. Richardson, RPh; Scott Schnuckle; Justin Weiss, PharmD; and Richard Bankowitz, MD, MBA, FACP
Executive-level pharmacy leaders in US managed care organizations identify how healthcare reform is driving changes in pharmacy benefit management.
Qian Cai, MS, MSPH; Chureen Carter, PharmD, MS; Azza AbuDagga, PhD, MHA; Brad Schenkel, MS; Megan Jones, PharmD, MPA; and Hiangkiat Tan, BPharm, MS
This study is an evaluation of the dosing patterns of ustekinumab among patients with psoriasis in a real-world setting.
Patient Advocacy
Myrl Weinberg, FASAE, CAE
Congress has passed a law designed to get advanced diagnostic tests to patients more quickly and to promote personalized care for patients.
Specialty Healthcare Benefits Council
Stephen Altenburger, PharmD; and Maureen Miller, MPH, BSN
The 2014 CMS Coverage Determination and Appeals audit will challenge plans providing Medicare Part D services, and could lead to a cascading impact much larger than audit failure alone.
Web Exclusives
Allison M. Bell, PharmD, MSc, BCPS; Mitra Corral, MS, MPH; John R. Penrod, PhD; Ying Zhang, MD, MSPH; Christopher R. Frei, PharmD, MSc, BCPS; Laurajo Ryan, PharmD, MSc, BCPS, CDE; Mark E. Salvati, PhD; and Jim M. Koeller, MS
We characterized the direct cost of stage 4 non-small cell lung cancer from 2000 to 2009, with a focus on drug treatments.
Ozgur Tunceli, PhD; David M. Kern, MS; Setareh A. Williams, PhD; Ned Pethick, MBA; Lisa Suchower, MA; and Sulabha Ramachandran, PhD
This study compares the initiation of asthma therapies in a real-world population.
Anna Kaltenboeck, MA; Jasmina Ivanova, MS; Howard Birnbaum, PhD; Yana Yushkina, BA; Frances Schwiep, BA; Kelly Bell, PharmD; and Nina Thomas, MPH
Controlling for baseline characteristics, saxagliptin patients had lower medical costs compared with sulfonylurea patients, and lower medical and total costs than sitagliptin patients.
Kristine Ogden, BS; Shuchita Kaila, PhD; and Nancy Neil, PhD
This model analysis explores the budget impact of prescribing single-pill fixed dose versus loose-dose combination triple therapies for hypertension.